Losee M, Kavanaugh M, Liu M, Borges N, et al. Outcome of Subsequent Therapies After (177)Lu-Vipivotide Tetraxetan for Metastatic Castrate-Resistant Prostate Cancer: A Tertiary Cancer Center Experience. Prostate 2025 Mar 18. doi: 10.1002/pros.24880.
PMID: 40103237